Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic (although some texts have referred to it as a typical antipsychotic) [10] medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and is sometimes used in low dosage to treat anxiety and mild depression.
However drawbacks to this exist as well. Once the drug is in the brain there is a point where it needs to be degraded to prevent overdose to the brain tissue. Also if the drug cannot pass back through the blood–brain barrier, it compounds the issues of dosage and intense monitoring would be required. For this to be effective there must be a ...
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...
Clobazam, sold under the brand names Frisium, Onfi and others, is a benzodiazepine class medication that was patented in 1968. [3] Clobazam was first synthesized in 1966 and first published in 1969.
An FDA advisory panel recently recommended the approval of Sanofi's multiple sclerosis drug, Lemtrada. However, that approval came among some mixed and contradictory opinions about the drug and ...
When Sanofi went live with its AI app, the quality of the data was not satisfactory. Some staff said the results were not reflective of their work, but it was their own data and they needed to fix it.
-The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed ...